

Curriculum Vitae

Name: Masoud
Surname: Etemadifar
Date of Birth: Sep 06, 1963
Place of Birth: Ardestan, Iran
Citizenship: Iranian

Address: Isfahan Multiple Sclerosis Clinic, Department
of Neurology, Al-Zahra Hospital, Soffeh Street, Isfahan, Iran.
Postal Code: 81744

Cell Phone: 0098 913 118 0249
Work Phone: 0098 311 626 6308
Fax: 0098 311 626 6308
Email: Etemadifar@med.mui.ac.ir

Present Title

- ❖ Professor of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran.

Appointments

- ❖ Director of Isfahan Multiple Sclerosis clinic, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. (2007 – present)
- ❖ Director of Isfahan Multiple Sclerosis Society, Isfahan, Iran. (2001 – present)
- ❖ Member of research council of Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. (2007 – present)
- ❖ Director of Al-Zahra hospital Neurology ward. (1994- present)
- ❖ Director of Isfahan Epilepsy Society. (2003- present)

Degrees and Training

- 2001-2002: Clinical Fellowship in Epilepsy, The University of Western Ontario, London, Ontario, Canada
- 1994-1997: Postgraduate education in clinical neurophysiology , Department of Neurology ,Isfahan University of medical sciences

- 1990-1993: Resident of Neurology, Department of Neurology ,Isfahan University of medical sciences
- 1989-1990: Internship, Isfahan University of medical sciences.
- 1984 - 1989: Doctor in Medicine (MD), Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Professional History

- 2003- present :Director of Isfahan Epilepsy Society.
- 2001-present : Director of Isfahan MS Society
- 1994-Present: Director of Neurology ward Al- Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
- 1995 - Present: Consultant Neurlogist, Saddoghi Hospital, Isfahan , Iran.
- 1995 - present: Consultant neurologist, Amiralmomenin medical center ,Isfahan , Iran.
- 1995 - 1996: Vice president, Al- Zahra Hospital, Isfahan University of Medical Sciences, Isfahan , Iran.

Affiliated Societies and Associations

1. Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Isfahan, Iran.
2. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
3. Isfahan University of Medical Sciences, Isfahan, Iran.
4. Isfahan Multiple Sclerosis Society (IMSS), Isfahan, Iran.
5. Iranian society of Neurologists, Tehran, Iran.
6. Iranian society of epilepsy , Tehran, Iran.
7. Iranian society of Multiple Sclerosis, Tehran, Iran.
8. Medical Council of Islamic Republic of Iran.
9. Pan-Asian Committee on Treatment and Research in Multiple Sclerosis

(PACTRIMS).

Awards, Prizes and Grants

- 2007: Prominent researcher of the University , Isfahan University of Medical Sciences.
- 1993 : First rank in the Iranian Neurologic Examination. Ministry of Health and welfare and Medical Education .

Administrative Posts

1. Member of “scientific Committee”; Pan Asian Committee on Treatment and Research in Multiple Sclerosis (PACTRIMS). (2009-present)
2. Member of “Executive and scientific Committee”; Iranian International MS Congresses. (2003-present)
3. Member of “Executive and scientific Committee”; Iranian Neurology and Electrophysiology Congresses (2004 -present)

Founding and planning

1. Isfahan Multiple Sclerosis Clinic, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran, July 2007.
2. Epilepsy ward and EEG monitoring, Kashani Hospital, Isfahan University of Medical Sciences, Isfahan, Iran, May 2005.
3. Isfahan Epilepsy Society, Isfahan, Iran, April 2003
4. Pain clinic, War disabled of Islamic revolution society, Isfahan, Iran, June 2003.
5. Isfahan Multiple Sclerosis Society, Isfahan, Iran, May 2002.
6. Neurodiagnostic ward, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran, Dec 1994.
7. Establishment of Neurology ward, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran, Nov 1994.
8. Epilepsy Clinic, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan ,Iran, June 1994.

Publications

Articles

1. The preventive role of topical timolol in treatment of migraine headaches. Etemadifar M, Abedi MR. *Journal of Research in Medical Sciences* 2005;10 (5): 288-291.
2. Spectrophotometry of cerebrospinal fluid may facilitate the diagnosis in neurological patients. Nematbakhsh M, Haghjoo-Javanmard S, Etemadifar M, Saboori M. *Journal of Research in Medical Sciences* 2006;11 (2): 122-123.
3. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. Hamzehloo A, Etemadifar M. *Archives of Iranian Medicine* 2006; 9 (2): 111-114.
4. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Etemadifar M, Janghorbani M, Shaygannejad V. *Acta Neurologica Scandinavica* 2006;113 (5): 283-287.
5. Prevalence of multiple sclerosis in Isfahan, Iran. Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F. *Neuroepidemiology* 2006;27 (1): 39-44 .
6. Early onset cardiotoxicity associated with mitoxantrone in patients with multiple sclerosis. Hamzehloo A, Etemadifar M. *Neurosciences* 2006; 11 (3): 221-222.
7. Mitoxantrone reduced disability in Iranian patients with multiple sclerosis. Hamzehloo A, Etemadifar M. *Archives of Iranian Medicine* 2007; 10 (1): 59-64.
8. Childhood-onset multiple sclerosis: report of 82 patients from Isfahan, Iran. *Arch Iran Med*. Etemadifar M, Nasr-Esfahani AH, Khodabandehlou R, Maghzi AH. 2007; 10 (2): 152-6.
9. Clinical and demographical characteristics of primary progressive multiple sclerosis in Isfahan, Iran. Maghzi AH, Etemadifar M, Saadatnia M. *Eur J Neurol*. 2007;14(4):403-7.
10. Conjugal multiple sclerosis in Isfahan, Iran: a population-based study. Maghzi AH, Etemadifar M, Shaygannejad V, Saadatnia M, Salehi M, Hassanzadeh A. *Mult Scler*. 2007; 13(5):673-5.
11. Efficacy of Gabapentin in the Treatment of SUNCT Syndrome. Cephalalgia. Etemadifar M, Maghzi AH, Ghasemi M, Chitsaz A, Kaji Esfahani M. 2008;28(12):1339-42.
12. Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis . Etemadifar M, Janghorbani M, Shaygannejad V. *Journal of Neurology* 2007;254 (12): 1723-1728.
13. Television-provoked epilepsy in children: a follow-up survey from Isfahan, Iran. Etemadifar M, Raoufi M, Maghzi AH, Ebrahimi A, Kaji-Esfahani M, Mousavi SA. *Arch Iran Med*. 2008; 11(6):649-53.
14. Acute demyelinating disorders of the central nervous system. Harris MK, Maghzi AH, Etemadifar M, Kelley RE, Gonzalez-Toledo E, Minagar A. *Curr Treat Options Neurol*. 2009; 11(1):55-63.

15. How frequent is celiac disease among epileptic patients? Emami MH, Taheri H, Kohestani S, Chitsaz A, Etemadifar M, Karimi S, Eshagi MA, Hashemi M. *J Gastrointestin Liver Dis.* 2008;17(4):379-82.
16. Neurosarcoidosis: Clinical Features, Diagnosis, and Management. Schwendimann RN, Harris MK, Elliott DG, Menon U, Gonzalez-Toledo E, Zivadinov R, Pressly TA, Kelley RE, Hoque R, Fowler M, Maghzi AH, Etemadifar M, Saadatnia M, Minagar A. *Am J Ther.* 2008;
17. Antiphospholipid antibodies: Paradigm in transition. Horstman LL, Jy W, Bidot CJ, Ahn YS, Kelley RE, Zivadinov R, Maghzi AH, Etemadifar M, Mousavi SA, Minagar A. *Neuroinflammation.* 2009; 6(1): 3.
18. Short-Term Effects of Prolonged Fasting on Multiple Sclerosis. Saadatnia M, Etemadifar M, Fatehi F, Ashtari F, Shaygannejad V, Chitsaz A, Maghzi AH. *Eur Neurol* 2009;61:230-232.
19. Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study. Maghzi A, Ghazavi H, Ahsan M, Etemadifar M, Mousavi S, Khorvash F, Minagar A. *Mult Scler.* 2010 Mar;16(3):359-61. Epub 2010 Jan 19
20. Role of platelets in neuroinflammation: a wide-angle perspective. Horstman LL, Jy W, Ahn YS, Zivadinov R, Maghzi AH, **Etemadifar** M, Steven Alexander J *Neuroinflammation.* 2010 Feb 3;7:10. Review.
21. Oropharyngeal dysphagia in multiple sclerosis. Poorjavad M, Derakhshandeh F, **Etemadifar** M, Soleymani B, Minagar A, Maghzi AH. *Mult Scler.* 2010 Mar;16(3):362-5.
22. Epidemiology of amyotrophic lateral sclerosis in Isfahan, Iran. Sajjadi M, **Etemadifar** M, Nemati A, Ghazavi H, Basiri K, Khoundabi B, Mousavi SA, *Eur J Neurol.* 2010 Jul;17(7):984-9. Epub 2010 Feb 28
23. Concentrations of nitric oxide metabolites in the serum of Iranian multiple sclerosis patients. Roghani M, Mahboudi F, Saharian MA, **Etemadifar** M, Esfahani AN, Nahrevanian H, *J Neurol Sci.* 2010 Jul 15;294(1-2):92-4.
24. Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection? Maghzi AH, Marta M, Bosca I, **Etemadifar** M, Dobson R, Maggiore C, Giovannoni G, Meier. *Pathophysiology.* 2011 Feb;18(1):13-20. Epub 2010 Jun 9.
25. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseier BC; GAP Study Group. *Eur J Neurol.* 2011 Jan;18(1):69-77. doi: 10.1111/j.1468-1331.2010.03110.x.
26. Features of Virchow-Robin spaces in newly diagnosed multiple sclerosis patients. **Etemadifar** M, Hekmatnia A, Tayari N, Kazemi M, Ghazavi A, Akbari M, Maghzi AH. *Eur J Radiol.* 2011 Nov;80(2):e104-8. Epub 2010 Jul 22.

27. Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study. **Etemadifar M**, Kazemi M, Chitsaz A, Hekmatnia A, Tayari N, Ghazavi A, Maghzi AH. *J Res Med Sci*. 2011 Jan;16(1):1-5.
28. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. **Etemadifar M**, Maghzi AH. *Mult Scler*. 2011 Aug;17(8):1022-7. Epub 2011 Apr 1.
29. Torque teno mini virus infection and multiple sclerosis. Komijani M, Bouzari M, **Etemadifar M**, Zarkesh-Esfahani H, Shaykh-Baygloo N, Ghazimorad A, Mostajeran M, Nasr-Azadani A, Maghzi AH. *Int J Neurosci*. 2011 Aug;121(8):437-41. Epub 2011 May 6.
30. Complement in neurobiology. Horstman LL, Jy W, Ahn YS, Maghzi AH, **Etemadifar M**, Alexander JS, McGee JC, Minagar A. *Front Biosci*. 2011 Jun 1;17:2921-60. Review
31. Recognition of the kind of stress coping in patients of multiple sclerosis. Hajhashemi A, Vaziripour HD, Baratian H, Kajbaf MB, **Etemadifar M**. *Indian J Psychol Med*. 2010 Jul;32(2):108-11.
32. Intrinsic third ventricular craniopharyngioma: A case report. Tayari N, **Etemadifar M**, Hekmatnia A, Mahzouni P, Maghzi AH, Rouzbahani R. *Int J Prev Med*. 2011 Jul;2(3):178-85.
33. Massive bilateral choroidal detachment induced by administration of topiramate. Dehghani A, Abtahi MA, Abtahi SH, Peyman A, **Etemadifar M**, Ghanbari H, Mohammadi Z. *Case Report Ophthalmol*. 2011 May;2(2):251-5. Epub 2011 Aug 9.
34. Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy. Keyhanian K, Davoudi V, Etemadifar M, Amin M. *Eur Neurol*. 2012 Jul 31;68(3):150-155. [Epub ahead of print]

35. Use of topiramate and risk of glaucoma: a case-control study. Abtahi SH, Abtahi MA, Roomizadeh P, Etemadifar M. *Am J Ophthalmol*. 2012 Aug;154(2):413. No
36. 25-hydroxyvitamin D Concentrations in Patients with Optic Neuritis as a Clinically Isolated Syndrome and Healthy Controls. Etemadifar M, Abtahi SH, Razmjoo H, Abtahi MA, Dehghani A, Salari M, Maghzi AH, Akbari M. *Int J Prev Med*. 2012 May;3(5):313-7.

37. Multiple sclerosis in Isfahan, Iran: Past, Present and Future. Etemadifar M, Abtahi SH. *Int J Prev Med.* 2012 May;3(5):301-2. No abstract available.
38. Epileptic seizures in early-onset multiple sclerosis. Etemadifar M, Abtahi SH, Tabrizi N. *Arch Iran Med.* 2012 Jun;15(6):381-3.
39. Effects of Topiramate on afferent visual pathways: controversies and uncertainties. Abtahi SH, Abtahi MA, Etemadifar M, Mazloumi M, Attarzadeh H. *Neurol Sci.* 2012 May 19.
40. Effect of Aquatic Exercise Training on Fatigue and Health-Related Quality of Life in Patients With Multiple Sclerosis. Kargarfard M, Etemadifar M, Baker P, Mehrabi M, Hayatbakhsh R. *Arch Phys Med Rehabil.* 2012 May 16.
41. Headache in migraine patients receiving topiramate: a mere migraine attack or a harbinger of ciliochoroidal effusion syndrome? Abtahi SH, Abtahi MA, Etemadifar M. *Acta Neurol Belg.* 2012 Mar 13. [Epub ahead of print] No abstract available.
42. Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription. Basiri K, Etemadifar M, Derakhshan F, Ashtari F, Shaygannejad V, Fatehi Z, Maghzi AH, Fatehi F. *Acta Med Iran.* 2012;50(2):97-100.
43. Topiramate and the vision: a systematic review. Abtahi MA, Abtahi SH, Fazel F, Roomizadeh P, Etemadifar M, Jenab K, Akbari M. *Clin Ophthalmol.* 2012;6:117-31. Epub 2012 Jan 12.

44. Interferon-beta-1b protects against multiple sclerosis-induced endothelial cells apoptosis. Haghjooy Javanmard S, Saadatnia M M, Homayouni V V, Nikoogoftar M M, Maghzi AH, Etemadifar M, Chaitanya VG, McGee JC, Minagar A, Alexander JS. *Front Biosci (Elite Ed)*. 2012 Jan 1;4:1368-74.
45. Cigarette smoking and the risk of multiple sclerosis: a sibling case-control study in Isfahan, Iran. Maghzi AH, Etemadifar M, Heshmat-Ghahdarijani K, Moradi V, Nonahal S, Ghorbani A, Minagar A. *Neuroepidemiology*. 2011;37(3-4):238-42. Epub 2011 Dec 7.
46. Multiple sclerosis and amyotrophic lateral sclerosis: is there a link? Etemadifar M, Abtahi SH, Akbari M, Maghzi AH. *Mult Scler*. 2012 Jun;18(6):902-4. Epub 2011 Dec 6.
47. Myasthenia Gravis during the Course of Neuromyelitis Optica. Etemadifar M, Abtahi SH, Dehghani A, Abtahi MA, Akbari M, Tabrizi N, Goodarzi T. *Case Rep Neurol*. 2011 Sep;3(3):268-73. Epub 2011 Oct 21.
48. Serum mercury level and multiple sclerosis. Attar AM, Kharkhaneh A, Etemadifar M, Keyhanian K, Davoudi V, Saadatnia M. *Biol Trace Elem Res*. 2012 May;146(2):150-3. Epub 2011 Nov 9.
49. Seroprevalence of NMO-IgG among patients with neuromyelitis optica and opticospinal multiple sclerosis. Etemadifar M, Mollabashi M, Chitsaz A, Behnamfar O, Bahrami E, Minagar A, Maghzi AH. *Clin Neurol Neurosurg*. 2012 Jan;114(1):17-20. Epub 2011 Oct 19.
50. Cesarean delivery may increase the risk of multiple sclerosis. Maghzi AH, Etemadifar M, Heshmat-Ghahdarijani K, Nonahal S, Minagar A, Moradi V. *Mult Scler*. 2012 Apr;18(4):468-71. Epub 2011 Oct 7.
51. Massive bilateral choroidal detachment induced by administration of topiramate. Dehghani A, Abtahi MA, Abtahi SH, Peyman A, Etemadifar M, Ghanbari H, Mohammadi Z. *Case Report Ophthalmol*. 2011 May;2(2):251-5. Epub 2011 Aug 9.

52. Intrinsic third ventricular craniopharyngioma: A case report. Tayari N, Etemadifar M, Hekmatnia A, Mahzouni P, Maghzi AH, Rouzbahani R. *Int J Prev Med.* 2011 Jul;2(3):178-85
53. IL-23 Plasma level measurement in relapsing remitting multiple sclerosis (RRMS) patients compared to healthy subjects. Shajarian M, Alsahebhosoul F, **Etemadifar M**, Sedaghat N, Shahbazi M, Firouzabadi FP, Dezashibi HM. *Immunol Invest.* 2014 Aug 1:1-9.
54. An epidemiological study of neuromyelitis optica in Isfahan. **Etemadifar M**, Dashti M, Vosoughi R, Abtahi SH, Ramagopalan SV, Nasr Z. *Mult Scler.* 2014 Jun 2. pii: 1352458514537699.
55. The results of core decompression treatment in patients with avascular necrosis of femoral head in patients at Isfahan City educational hospitals in 2010-2011. **Etemadifar M**, Kooskzari M, Khalilollah N, Ali MK, Mahsa B. *Adv Biomed Res.* 2014 Mar 25;3:93. doi: 10.4103/2277-9175.129363. eCollection 2014.
56. Prevalence of Lhermitte's sign in multiple sclerosis versus neuromyelitis optica. Etemadifar M, Mehrbod N, Dehghani L, Golabbakhsh A, Fereidan-Esfahani M, Akbari M, Nasr Z. *Iran J Neurol.* 2014;13(1):50-1
57. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis. Honardoost MA, Kiani-Esfahani A, Ghaedi K, Etemadifar M, Salehi M. *Gene.* 2014 Jul 10;544(2):128-33. doi: 10.1016/j.gene.2014.04.069. Epub 2014 Apr 30.
58. Islamic fasting and multiple sclerosis. Jahromi SR, Sahraian MA, Ashtari F, Ayromlou H, Etemadifar M, Ghaffarpour M, Mohammadianinejad E, Nafissi S, Nickseresht A, Shaygannejad V, Togha M, Torabi HR, Ziaie S. *BMC Neurol.* 2014 Mar 22;14:56. doi: 10.1186/1471-2377-14-56.
59. Is it necessary to perform connective tissue disorders laboratory tests when a patient experiences the first demyelinating attack? Etemadifar M, Fatemi A, Hashemijazi H, Kazemizadeh A. *J Res Med Sci.* 2013 Jul;18(7):617-20.
60. Multiple sclerosis in Isfahan, Iran: an update. Etemadifar M, Abtahi SH, Akbari M, Murray RT, Ramagopalan SV, Fereidan-Esfahani M. *Mult Scler.* 2013 Dec 10;20(8):1145-1147.

61. Neurological manifestations in patients with antiphospholipid syndrome. Etemadifar M, Dehghani L, Tahani S, Toghianifar N, Rahaimi M, Eskandari N. *Iran J Neurol.* 2013;12(4):172-5.
62. The relation between peptide hormones and sex hormone in patients with multiple sclerosis. Eftekhari E, Etemadifar M, Ebrahimi A, Baradaran S. *Iran J Neurol.* 2013;12(2):60-5
63. Epidemiology of multiple sclerosis in Iran: a systematic review. Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, Fereidan-Esfahani M. *Eur Neurol.* 2013;70(5-6):356-63. doi: 10.1159/000355140. Epub 2013 Nov 2.
64. Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis. Etemadifar M, Afzali P, Abtahi SH, Ramagopalan SV, Nourian SM, Murray RT, Fereidan-Esfahani M. *Eur J Paediatr Neurol.* 2014 Mar;18(2):119-25. doi: 10.1016/j.ejpn.2013.09.001. Epub 2013 Oct 7.
65. Does levetiracetam decrease of the rubral tremor in patients with multiple sclerosis. Chitsaz A, Mehrbod N, Etemadifar M, Najafi M. *J Res Med Sci.* 2013 Mar;18(Suppl 1):S78-80.
66. Vitamin d: shining a light on clinical and sex specific effects in multiple sclerosis? Fereidan-Esfahani M, Ramagopalan SV, Etemadifar M, Sadri S, Abtahi SH. *Int J Prev Med.* 2013 May;4(5):499-500. No abstract available.
67. Multiple sclerosis among Iranian-Arabs and Persians of Khuzestan: is there any ethnic difference? Fereidan-Esfahani M, Abtahi SH, Nourian SM, Etemadifar M. *Clin Neurol Neurosurg.* 2013 Oct;115(10):2309-10. doi: 10.1016/j.clineuro.2013.06.021. Epub 2013 Jul 20
68. Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study. Tabrizi N, Etemadifar M, Ashtari F, Zahed A, Etemadifar F. *J Res Med Sci.* 2012 Sep;17(9):828-33.
69. Can vitamin d suppress endothelial cells apoptosis in multiple sclerosis patients? Dehghani L, Meamar R, Etemadifar M, Sheshde ZD, Shaygannejad V, Sharifkhan M, Tahani S. *Int J Prev Med.* 2013 May;4(Suppl 2):S211-5.
70. Necrotizing external otitis: a case series. Soheilipour S, Meidani M, Derakhshandi H, Etemadifar M. *B-ENT.* 2013;9(1):61-6

71. Resistance training and vibration improve muscle strength and functional capacity in female patients with multiple sclerosis. Eftekhari E, Mostahfezian M, Etemadifar M, Zafari A. *Asian J Sports Med.* 2012 Dec;3(4):279-84.
72. Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study. Etemadifar M, Sayahi F, Abtahi SH, Shemshaki H, Dorooshi GA, Goodarzi M, Akbari M, Fereidan-Esfahani M. *Int J Neurosci.* 2013 Jul;123(7):480-6. doi: 10.3109/00207454.2013.764499. Epub 2013 Feb 11
73. Association of urodynamic findings in new onset multiple sclerosis with subsequent occurrence of urinary symptoms and acute episode of disease in females. Tadayyon F, Etemadifar M, Bzeih H, Zargham M, Nouri-Mahdavi K, Akbari M, Tadayyon B. *J Res Med Sci.* 2012 Apr;17(4):382-5
74. Pediatric multiple sclerosis with primary progressive course--report of a retrospective cohort study in Iran. Etemadifar M, Afzali P, Tabrizi N, Hosseini SA. *Neuropediatrics.* 2013 Jun;44(3):167-70. doi: 10.1055/s-0032-1329614. Epub 2012 Dec 19.
75. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. Derakhshandi H, Etemadifar M, Feizi A, Abtahi SH, Minagar A, Abtahi MA, Abtahi ZA, Dehghani A, Sajjadi S, Tabrizi N. *Acta Neurol Belg.* 2013 Sep;113(3):257-63. doi: 10.1007/s13760-012-0166-2. Epub 2012 Dec 19.
76. Linkage of multiple sclerosis and guillain-barre syndrome: a population-based survey in isfahan, iran. Etemadifar M, Roomizadeh P, Abtahi SH, Sajjadi S, Abedini A, Golabbakhsh A, Fereidan-Esfahani M, Akbari M. *Autoimmune Dis.* 2012;2012:232139. doi: 10.1155/2012/232139. Epub 2012 Nov 4.
77. Hemiballismus, Hyperphagia, and Behavioral Changes following Subthalamic Infarct. Etemadifar M, Abtahi SH, Abtahi SM, Mirdamadi M, Sajjadi S, Golabbakhsh A, Savoj MR, Fereidan-Esfahani M, Nasr Z, Tabrizi N. *Case Rep Med.* 2012;2012:768580. doi: 10.1155/2012/768580. Epub 2012 Oct 18.
78. Epileptic seizures in multiple sclerosis: a population-based survey in Iran. Etemadifar M, Abtahi SH, Roomizadeh P. *Acta Neurol Belg.* 2013 Sep;113(3):271-8. doi: 10.1007/s13760-012-0146-6. Epub 2012 Oct 31.
79. Anti-aquaporin-4 IgG in Patients Presenting with Unilateral Optic Neuritis: A Cohort Study. Etemadifar M, Abtahi MA, Razmjoo H, Abtahi SH, Dehghani AR, Abtahi ZA, Akbari M, Mazaheri S, Maghzi AH. *Int J Prev Med.* 2012 Sep;3(9):612-5.

80. Late-onset multiple sclerosis in Isfahan, Iran. Etemadifar M, Abtahi SH, Minagar A, Akbari M, Masaeli A, Tabrizi N. Arch Iran Med. 2012 Oct;15(10):596-8.
81. Rapid exacerbation of multiple sclerosis following the initiation of interferon- β : report of nine cases. Etemadifar M, Sarrami AH. J Res Med Sci. 2011 Dec;16(12):1619-22.

Twenty more papers are published in local and national scientific journals in Persian and English.

A

Books and book Chapters

1. Etemadifar M and other neurology academics of Isfahan University of Medical sciences. "Neurological diseases". Isfahan University of Medical sciences press, Isfahan, Iran,2001 [in Persian].
2. Etemadifar M and Ashtari F." Diagnosis and treatment of Multiple Sclerosis". Isfahan University of Medical sciences press, Isfahan, Iran,2002 [in Persian].
3. Etemadifar M, khodabandeloo R ."Stroke". Isfahan University of Medical sciences press, Isfahan, Iran,2003 [in Persian].
4. Etemadifar M, Chitsaz A. "Multiple Sclerosis". Isfahan University of Medical sciences press, Isfahan, Iran,2000 [in Persian].
5. Eftekhari E, Etemadifar M. "Rehabilitation in Multiple Sclerosis". Islamic Azad University of Najafabad press, 2008 [in Persian].
6. Saadatnia M, Etemadifar M, **Maghzi AH**. Multiple sclerosis in Isfahan, Iran. In "The Neurobiology of Multiple Sclerosis". Ed. Minagar A. (2007) Elsevier, San Diego, California, pp 357-75.

Abstracts

More than 100 abstracts in national and international congresses. Below are the most recent 20 abstract presented in international congresses:

1. Maghzi AH, Etemadifar M, Shaygannejad V, Saadatnia M. Conjugal multiple sclerosis in Isfahan, Iran: a population-based study. *Eur J Neurol* 2006, 13 (Suppl. 2): 169–294; P2276: 243. (Poster presented at the 10th Congress of the European Federation of Neurological Societies (EFNS), Scotland, UK, September 2-5, 2006)
2. Saadatnia M, Etemadifar M, Maghzi AH, Ebrahimi A, Shaygannejad V, Basiri K. Late onset multiple sclerosis in Isfahan, Iran. *J Neurol* 2007, 254 (Suppl. 3) : III/1–III/212; P227: III/57. (Poster presented at Seventeenth Meeting of the European Neurological Society (ENS), Rhodes ,Greece, June 16-20, 2007)
3. Maghzi AH, Etemadifar M, Saadatnia M. Clinical study of primary progressive multiple sclerosis in Isfahan, Iran. *J Neurol* 2007, 254 (Suppl. 3): III/1–III/212; P532; III/134. . (Poster presented at Seventeenth Meeting of the European Neurological Society (ENS), Rhodes, Greece, June 16-20, 2007)
4. Etemadifar M, Maghzi AH. Clinical Study of Early Onset Multiple Sclerosis In Isfahan,Iran. *Eur J Neurol* 2007, 14 (Suppl. 1): 165–301; P2449: 274. (Poster presented at 11th Congress of the European Federation of Neurological Societies (EFNS),Brussels, Belgium, August 25-28,2007)
5. Ardestani P, Etemadifar M, Nejadnik H, Maghzi AH, Basiri K, Ebrahimi A, Davoodi M. Narcolepsy as the initial presentation of multiple sclerosis. *Sleep Biol Rhythms* 2007,5: A1–A189; PO558: A166. (Poster presented at worldsleep07: The 5th World Congress of the World Federation of Sleep Research and Sleep Medicine Societies, Cairns, Australia , 2-6 September 2007.)
6. Maghzi AH, Etemadifar M. Features of Multiple Sclerosis in the Armenian community of Isfahan, Iran. *Mult Scler* 2007 ,13 (Suppl.2): P 331. (Poster presented at 23rd European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Prague, Czech Republic, October 11–14, 2007.)
7. Saadatnia M, Valian A, Najafi MR, Etemadifar M, Ronaghi A, Maghzi AH, Najafi F. Correlation of CD24 Gene Alleles with Oligoclonal IgG Bands and IgG Index in the Cerebrospinal Fluid of Iranian Multiple Sclerosis Patients. *Mult Scler* 2007 , 13 (Suppl.2): P 669. (Poster presented at 23rd European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Prague, Czech Republic, October 11–14, 2007.)
8. Basiri K, Etemadifar M, Zarghami N, Maghzi A, Nilforoushan N, Jazebi N. Co-occurrence of multiple sclerosis and myasthenia gravis in Isfahan, Iran. *Mult Scler*

- 2007, 13 (Suppl.2):P 318. (Poster presented at 23rd European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Prague, Czech Republic, October 11–14, 2007.)
9. Davoudi V, Keyhanian K, Amin M, Etemadifar M, Maghzi A, Basiri K. Increased risk of multiple sclerosis in medical staff. *Mult Scler* 2007, 13 (Suppl.2):P 317. (Poster presented at 23rd European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Prague, Czech Republic, October 11–14, 2007.)
 10. Keyhanian K, Davoudi V, Amin M, Etemadifar M, Maghzi A, Basiri K. Multiple sclerosis and pregnancy: a long term follow up of MS patients. *Mult Scler* 2007, 13 (Suppl.2): P 319. (Poster presented at 23rd European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Prague, Czech Republic, October 11–14, 2007.)
 11. Etemadifar M, Ebrahimi A, Memar Ardestani P, Maghzi AH, Jaffe SL, Nejadnik H, M. Kaji Esfahani. A study of 35 cases of cavernous angioma from Isfahan, Iran. *Neurosciences* 2008; 13 (Suppl.1): 13. (Poster presented at 16th Saudi Neuroscience Symposium, Riyadh, Saudi Arabia, January 21-24, 2008.)
 12. Etemadifar M, Kaji Esfahani M, Raoufi M, Maghzi AH, Ebrahimi A. Television provoked epilepsy in children. *Neurosciences* 2008; 13 (Suppl.1): 44-45. (Poster presented at 16th Saudi Neuroscience Symposium, Riyadh, Saudi Arabia, January 21-24, 2008.)
 13. Maghzi AH, Etemadifar M, Kaji Esfahani M, Ghasemi M, Chitsaz A. Efficacy of Gabapentin in the Treatment of SUNCT Syndrome. *Neurology* 2008, 70 ;11 (Suppl.1): P08.190. (Poster presented at American Academy of Neurology (AAN) 60th Annual Meeting, Chicago, Illinois, USA, April 12 - 19, 2008.)
 14. Keyhanian K, Davoudi V, Etemadifar M, Maghzi AH, Amin M. Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Fullterm Pregnancy. *Neurology* 2008, 70; 11 (Suppl.1): P06.158. (Poster presented at American Academy of Neurology (AAN) 60th Annual Meeting, Chicago, Illinois, USA, April 12 - 19, 2008.)
 15. Etemadifar M, Hajghasemi F, Maghzi AH, Kaji Esfahani M. Neurological manifestations of the antiphospholipid syndrome: a study from Isfahan, Iran. *J Neurol* 2008, P 638 (Poster presented at Eighteenth Meeting of the European Neurological Society (ENS), Nice, France, June 7-11, 2008.)
 16. Etemadifar M, Maghzi AH, Nemati A, Sajjadi Jazi SM, Chitsaz A. Familial multiple sclerosis in Isfahan, Iran. *Mult Scler* 2008; 14: S63-S64, P119. (Poster presented at World Congress for Treatment and Research in Multiple Sclerosis (WCTRIMS), the

first joint meeting of ACTRIMS, ECTRIMS and LACTRIMS, Montreal, Canada, September 17–20, 2008.)

17. Etemadifar M, Maghzi AH, Chitsaz N, Kaji Esfahani M. The risk of multiple sclerosis for the offspring of consanguineous mating. *Mult Scler* 2008; 14: S64, P120. (Poster presented at World Congress for Treatment and Research in Multiple Sclerosis (WCTRIMS), the first joint meeting of ACTRIMS, ECTRIMS and LACTRIMS, Montreal, Canada, September 17–20, 2008.)
18. Maghzi AH, Etemadifar M, Ghazavi H, Ahsan M, Mousavi SA. Sex ratio of multiple sclerosis: a study from Isfahan, Iran. *Mult Scler* 2009; 15: 137, P-2. (Poster presented at Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Kuala Lumpur, Malaysia, November 21–22, 2008.)
19. Maghzi AH, Etemadifar M, Sadrearhami S, Kaji Esfahani M, Sahraian MA. Clinical and demographic characteristics of multiple sclerosis with late onset. *Mult Scler* 2009; 15: 139, P-12. (Poster presented at Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Kuala Lumpur, Malaysia, November 21–22, 2008.)
20. Sahraian MA, Abedini M, Maghzi AH, Moinfar Z, Gheini MR, Etemadifar M, Motamedi M, Farsam M. Evaluation of serum and cerebrospinal fluid magnesium and zinc concentration in patients with multiple sclerosis: a case-control study. *Mult Scler* 2009; 15: 143, P-22. (Poster presented at Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Kuala Lumpur, Malaysia, November 21–22, 2008.)

Oral presentations and Invited lectures

1. Various oral presentations in national and international congresses on Multiple Sclerosis, Epilepsy and other neurological conditions.
2. Various invited lectures in national symposia on Multiple Sclerosis.

Thesis Supervision

More than 100 thesis supervision for students and residents at Isfahan University of Medical Sciences, Isfahan ,Iran, (1999- Present).

